Integrated personalized cell technologies for improving health outcomes in children and adults


Photo of Jacques Galipeau

Jacques Galipeau, MD
Director, Program for Advanced Cell Therapy (PACT)

Jacques Galipeau, M.D. FRCP(C) is the Don and Marilyn Anderson Professor of Oncology within the Department of Medicine and UW Carbone Comprehensive Cancer Center at the University of Wisconsin in Madison, and is the inaugural Associate Dean for Therapeutics Development at the University of Wisconsin School of Medicine & Public Health

Prior to coming to UW Madison, Dr. Galipeau was at the Winship Cancer Center at Emory University, where he founded the Emory Personalized Immunotherapy Center and launched clinical trials of MSC-based treatments for Crohn’s disease and graft versus host disease (GVHD), a life-threatening complication of bone marrow transplant. Prior to this, he was a faculty member at McGill University in Montreal, Canada. He is an internationally recognized expert in translational development of cell therapies and the sponsor of a series of FDA-sanctioned clinical trials examining the use of autologous marrow-derived mesenchymal stromal cells for immune disorders, including Crohn’s disease and graft vs host disease. Dr. Galipeau has also developed the field of fusion engineered cytokines known as fusokines, as a novel pharmaceutical means of treating immune disorders and cancer. Dr. Galipeau is the director of the University of Wisconsin Advanced Cell Therapy Program whose mission is to develop personalized cell therapies for immune and malignant disorders and to promote and deploy first-in-human clinical trials of UW cell therapy innovations to improve outcomes for children and adults.

Photo of Inga Hoffman

Inga Hofmann, MD
Medical Director, Program for Advanced Cell Therapy (PACT)

Dr. Hofmann is an assistant professor of pediatric hematology, oncology and the Director of Pediatric Stem Cell Transplant program at the UW School of Medicine and Public Health (SMPH). She received her MD degree from Albert Ludwigs University of Freiburg, Germany and completed her pediatric residency at the University of California in San Francisco. Dr. Hofmann also completed her clinical fellowship in pediatric hematology and oncology at the Dana-Farber/Boston Children’s Cancer and Blood Disorder Center at Harvard Medical School, and her post-doctoral fellowship in hematopathology and pediatric hematopathology at the Brigham and Women’s Hospital in Boston and Boston Children’s Hospital. At Boston Children’s Hospital, she discovered her passion for cell therapy. She became devoted to the rare childhood bone marrow failure and myelodysplastic syndromes (MDS). Dr.Hofmann created a national registry of patients and their blood samples in the hopes of completing research to help develop treatments for these often fatal diseases.As the Medical Director, Dr. Hofmann manages the interaction between patients, SMPH, American Family Children’s Hospital clinical trials office and PACT as the program manufactures a variety of cell types to conduct first-in-human clinical trials.

Photo of Rupa Pike

Nirupama (Rupa) Pike, PhD
Director of Cell Manufacturing, Program for Advanced Cell Therapy (PACT)

Dr. Pike earned her doctorate degree from Harvard University and completed her post-doctoral fellowship at Ligand Pharmaceuticals. At Ligand Pharmaceuticals, she was part of the team that designed novel hematopoietic screening assays for erythropoietin and thrombopoietin in partnership with GlaxoSmithKline, a part of the program for development of Promacta®. Dr. Pike gained extensive industry and biotechnology experience by working at Life Technologies, Thermo Fisher Scientific and Stem Cell Theranostics. In her past roles she successfully managed R&D laboratory operations, new product development, quality management, infrastructure development, customer relations and business development. She has worked with a hematopoietic stem cells, mesenchymal stem cells and induced pluripotent stem cells for regenerative medicine and drug discovery applications. Dr. Pike’s role is be to oversee operations of the GMP Cell Manufacturing Laboratory for advanced cell manufacturing of hematopoietic cells, mesenchymal stem cells and other cell types that will be used in first-in-human clinical trials. She also assists UW Madison researchers, clinicians and other academic/industry partners by providing manufacturing services, designing novel assays, providing scale-out and scale-up options for specific cell types and assisting in filing IND applications.

Photo-Crystal Weinberger

Crystal Weinberger, MBA
Program Administrator

A native of Wisconsin, Crystal graduated from the University of Wisconsin – Madison in 2004 with Bachelor’s degrees in Journalism and Political Science. She completed her Master’s in Business Administration in 2013 from the Carlson School of Management at the University of Minnesota. Her professional experience includes almost 15 years of administrative service in the fields of healthcare, nonprofit management and academic medicine.